Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G



 
Frazier Life Sciences Public Fund, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:11/16/2026
 
FHMLSP, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:11/16/2026
 
FHMLSP, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:11/16/2026
 
Frazier Life Sciences X, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:11/16/2026
 
FHMLS X, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:11/16/2026
 
FHMLS X, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date:11/16/2026
 
Frazier Life Sciences XI, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:11/16/2026
 
FHMLS XI, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:11/16/2026
 
FHMLS XI, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:11/16/2026
 
James N. Topper
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney
Date:11/16/2026
 
Patrick J. Heron
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G/A filed on May 15, 2025)